Ascrinvacumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Ascrinvacumab
Monoclonal antibody
Type?
SourceHuman
Targetactivin receptor-like kinase 1
Clinical data
SynonymsPF-03446962
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6396H9850N1694O2012S44
Molar mass144.1 kg/mol g·mol−1

Ascrinvacumab (PF-03446962) is a monoclonal antibody designed for the treatment of cancer.[1]

This drug was developed by Pfizer Inc.

References[edit]